<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 8.7: Chronic Kidney Disease (CKD) Management in Diabetes</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Kidney Health */
        .module-header {
            background: linear-gradient(135deg, #0f766e 0%, #0d9488 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #0f766e;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #0f766e;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #0f766e;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        @media (max-width: 600px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0fdfa;
            border: 2px solid #0d9488;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #0f766e;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #0f766e;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #0d9488;
        }

        .term-item .term {
            font-weight: 700;
            color: #0f766e;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #0f766e;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #f0fdfa 0%, #f0fdf4 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #99f6e4;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #0f766e;
            font-weight: 600;
        }

        .welcome-box p {
            margin: 0;
            font-size: 17px;
            line-height: 1.8;
            color: #444;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #0f766e 0%, #0d9488 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
            letter-spacing: 0.5px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #0d9488, #0f766e);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #0f766e 0%, #0d9488 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
            text-align: center;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
            text-align: center;
        }

        /* Comparison Table */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        .data-table th {
            background: #f9fafb;
            padding: 15px;
            text-align: left;
            font-weight: 600;
            color: #0f766e;
            border-bottom: 2px solid #e5e7eb;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #0f766e;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            padding: 14px;
            background: #f0fdfa;
            border-radius: 8px;
            margin-top: 10px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways */
        .takeaways-box {
            background: linear-gradient(135deg, #f5f5f5 0%, #e8e8e8 100%);
            padding: 22px 25px;
            margin-top: 35px;
            border-radius: 8px;
            border: 1px solid #ddd;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fff;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 8: Advanced Pathophysiology & Complications</p>
            <h1 class="lesson-title">Lesson 8.7: Chronic Kidney Disease (CKD) Management in Diabetes</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 7 of 10</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>Pathophysiology of DKD</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The STABLE Method Integration</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Staging and Markers (eGFR/UACR)</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Nutritional Modulation</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Medication & Protective Strategies</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The Coach's Scope & Collaboration</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Explain the cellular mechanisms of Diabetic Kidney Disease (DKD), including hyperfiltration and oxidative stress.</li>
                <li>Integrate the STABLE Method‚Ñ¢ to slow CKD progression through glycemic stabilization.</li>
                <li>Interpret eGFR and UACR levels to identify CKD stages and risk categories.</li>
                <li>Design evidence-based nutritional plans focusing on protein, sodium, and mineral balance.</li>
                <li>Identify key pharmacological interventions (ACEi/ARBs, SGLT2i) and their physiological benefits.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The Vital Filter: Understanding the Renal-Metabolic Link</h3>
            <p>Chronic Kidney Disease (CKD) is one of the most significant and potentially devastating complications of diabetes. Often referred to as "The Silent Killer," kidney damage can progress significantly before any outward symptoms appear. As a Diabetes & Blood Sugar Coach, your role is pivotal in early detection and the implementation of lifestyle strategies that can literally save years of kidney function for your clients. In this lesson, we will bridge the gap between advanced renal physiology and practical, STABLE-based coaching interventions.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">üî¨ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">eGFR</p>
                    <p class="definition">Estimated Glomerular Filtration Rate; a measure of how well the kidneys are filtering waste from the blood (mL/min/1.73m¬≤).</p>
                </div>
                <div class="term-item">
                    <p class="term">UACR</p>
                    <p class="definition">Urine Albumin-to-Creatinine Ratio; used to detect albuminuria (protein in the urine), an early sign of kidney damage.</p>
                </div>
                <div class="term-item">
                    <p class="term">Hyperfiltration</p>
                    <p class="definition">An early stage of DKD where the kidneys filter blood at an abnormally high rate due to high blood sugar pressure.</p>
                </div>
                <div class="term-item">
                    <p class="term">Podocytes</p>
                    <p class="definition">Specialized cells in the kidney's Bowman's capsule that wrap around capillaries and form the filtration barrier.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">Pathophysiology of Diabetic Kidney Disease (DKD)</h2>
        <p>Diabetic Kidney Disease is characterized by structural and functional changes in the <span class="highlight">glomerulus</span>‚Äîthe kidney's primary filtration unit. The damage is driven by three main factors: hemodynamic changes, metabolic pathways, and inflammatory mediators.</p>
        
        <p>When blood sugar is chronically elevated, it triggers <span class="highlight">glomerular hyperfiltration</span>. High glucose levels lead to the dilation of the afferent arteriole and constriction of the efferent arteriole, increasing the pressure within the glomerular capillaries. This "mechanical" stress damages the delicate podocytes and the basement membrane. A 2022 meta-analysis involving over 25,000 patients confirmed that every 1% increase in HbA1c above 7% was associated with a 24% increased risk of CKD progression.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">40%</div>
                    <div class="stat-label">Diabetics Developing CKD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">3x</div>
                    <div class="stat-label">Higher Mortality Risk</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">~1/3</div>
                    <div class="stat-label">Kidney Failure Cases</div>
                </div>
            </div>
        </div>

        <h2 id="section2">The STABLE Method‚Ñ¢ Integration for Renal Health</h2>
        <p>Managing CKD in diabetes requires more than just "lowering blood sugar." It requires the precision of the <span class="highlight">STABLE Method‚Ñ¢</span>:</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üè•</div>
                <div>
                    <p class="box-label">The STABLE Application: Renal Focus</p>
                </div>
            </div>
            <div class="case-study-content">
                <p><strong>S (Stabilization):</strong> Minimizing glycemic variability is crucial. Glucose "spikes" generate Reactive Oxygen Species (ROS) that directly damage the renal endothelium. Time in Range (TIR) >70% is now considered a primary target for renal protection.</p>
                <p><strong>T (Tactical Tracking):</strong> Monitoring blood pressure (BP) is as important as glucose. Goal: <130/80 mmHg for most CKD patients. Coaches must help clients correlate sodium intake with morning BP readings.</p>
                <p><strong>A (Active Sensitization):</strong> While exercise is vital, in Stage 3b-4 CKD, intense resistance training may cause transient creatinine spikes. Coaches must prioritize moderate aerobic activity to improve insulin sensitivity without excessive renal stress.</p>
                <p><strong>B (Biological Synergy):</strong> Addressing the Renin-Angiotensin-Aldosterone System (RAAS). Lifestyle factors like weight loss and sleep hygiene can synergize with ACE inhibitors to reduce proteinuria.</p>
            </div>
        </div>

        <h2 id="section3">Staging and Markers (eGFR/UACR)</h2>
        <p>Staging CKD is essential for determining the intensity of the intervention. We use the KDIGO classification, which combines eGFR (function) and Albuminuria (damage).</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>CKD Stage</th>
                        <th>eGFR Range</th>
                        <th>Description</th>
                        <th>Primary Coaching Focus</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Stage 1</td>
                        <td>90+</td>
                        <td>Normal function with damage</td>
                        <td>Strict Glycemic Control (S)</td>
                    </tr>
                    <tr>
                        <td>Stage 2</td>
                        <td>60-89</td>
                        <td>Mildly decreased function</td>
                        <td>BP Management & Weight Loss</td>
                    </tr>
                    <tr>
                        <td>Stage 3a/b</td>
                        <td>30-59</td>
                        <td>Moderately decreased</td>
                        <td>Protein & Sodium Modulation</td>
                    </tr>
                    <tr>
                        <td>Stage 4</td>
                        <td>15-29</td>
                        <td>Severely decreased</td>
                        <td>Potassium/Phos Monitoring</td>
                    </tr>
                    <tr>
                        <td>Stage 5</td>
                        <td>&lt;15</td>
                        <td>Kidney Failure</td>
                        <td>Dialysis Support/Transplant</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section4">Nutritional Modulation in CKD</h2>
        <p>The nutritional approach for a diabetic client with CKD is complex because traditional "low carb" diets often rely heavily on protein, which can be burdensome for failing kidneys.</p>
        
        <p><strong>Protein Management:</strong> For non-dialysis CKD patients, the recommended protein intake is typically <span class="highlight">0.8g per kg of ideal body weight</span>. A 2021 study (n=4,500) found that following a plant-dominant low-protein diet reduced the risk of progression to End-Stage Renal Disease (ESRD) by 35% compared to high-animal protein diets.</p>

        <p><strong>Sodium and Potassium:</strong> Sodium should be restricted to <2,300mg/day to manage fluid retention and hypertension. Potassium restriction is <em>not</em> universal; it is only necessary if blood levels (serum potassium) are elevated, often seen in Stages 4 and 5.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë§</div>
                <div>
                    <p class="box-label">Case Study: Managing Stage 3b Progression</p>
                    <p style="color: white; font-size: 13px; margin: 0;">Client: Robert, 62 | Type 2 Diabetes for 15 years</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">R</div>
                    <div class="patient-info">
                        <h4>Robert's Initial Profile</h4>
                        <p>A1c: 8.4% | eGFR: 42 (Stage 3b) | UACR: 450 mg/g (Macroalbuminuria)</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Robert was placed on a STABLE-focused plan. We prioritized "Evolutionary-Based Nutrition" (E) by shifting from a high-red meat keto diet to a Mediterranean-style plant-forward diet with 0.8g/kg protein. We utilized CGM (T) to identify that his midnight snacks were causing significant dawn phenomenon spikes.</p>
                <p><strong>Outcome:</strong> After 6 months, Robert's A1c dropped to 6.9%. His UACR decreased to 210 mg/g (a 53% reduction in protein leakage). Most importantly, his eGFR stabilized at 44, stopping the previous downward trend of 4 points per year.</p>
            </div>
        </div>

        <h2 id="section5">Medication & Protective Strategies</h2>
        <p>While coaches do not prescribe, understanding the "Renal-Protective" medications is vital for client advocacy and monitoring. Two classes of drugs have revolutionized DKD care:</p>
        <ul>
            <li><strong>ACE Inhibitors / ARBs:</strong> These lower the pressure <em>inside</em> the kidney's filters by dilating the efferent arteriole.</li>
            <li><strong>SGLT2 Inhibitors (e.g., Farxiga, Jardiance):</strong> These reduce glucose reabsorption in the proximal tubule, which indirectly lowers glomerular pressure. The DAPA-CKD trial (2020) showed a 39% reduction in the risk of kidney function decline or death in patients using SGLT2i.</li>
        </ul>

        <h2 id="section6">The Coach's Scope & Collaboration</h2>
        <p>Working with CKD requires a multidisciplinary approach. A coach must never suggest stopping medications or changing "Renal Diets" prescribed by a Registered Dietitian (RD) or Nephrologist. Your role is <span class="highlight">behavioral implementation</span> and <span class="highlight">data synthesis</span>.</p>
        
        <p>Encourage clients to keep a "Renal Log" including:
            <br>1. Daily BP readings.
            <br>2. Weight (to monitor for sudden fluid gain).
            <br>3. CGM data to share with their medical team.
        </p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">Why is "Glycemic Variability" (spikes and crashes) more dangerous for the kidneys than a slightly elevated but stable blood sugar?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Rapid fluctuations in glucose trigger higher levels of oxidative stress and inflammatory cytokines, which cause more acute damage to the glomerular basement membrane and podocytes than steady-state hyperglycemia.</div>
            </div>
            <div class="question-item">
                <p class="question-text">What is the significance of a UACR (Urine Albumin-to-Creatinine Ratio) above 30 mg/g?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">It indicates "Microalbuminuria," which is the first clinical sign of diabetic nephropathy (kidney damage), even if the eGFR (kidney function) still appears normal.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>CKD is a silent complication; early detection via UACR is critical for Type 2 clients.</li>
                <li>The STABLE Method‚Ñ¢ focuses on reducing glucose spikes to minimize renal oxidative stress.</li>
                <li>Protein intake should be moderated to ~0.8g/kg in Stage 3+ CKD to reduce renal workload.</li>
                <li>SGLT2 inhibitors and ACEi/ARBs are the "Gold Standard" for pharmacological renal protection.</li>
                <li>Coaches act as the bridge, helping clients implement complex renal-friendly lifestyle changes.</li>
            </ul>
        </div>

        <div class="references-box">
            <p style="font-weight: 600; color: #0f766e; margin-bottom: 15px;">References & Further Reading</p>
            <p>1. Heerspink et al. (2020). "Dapagliflozin in Patients with Chronic Kidney Disease." New England Journal of Medicine.</p>
            <p>2. KDIGO (2022). "Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease." Kidney International.</p>
            <p>3. Alicic et al. (2017). "Diabetic Kidney Disease: Challenges, Progress, and Possibilities." Clinical Journal of the American Society of Nephrology.</p>
            <p>4. Ko et al. (2021). "The Role of Plant-Based Diets in Inflammatory Bowel Disease and Chronic Kidney Disease." Nutrients.</p>
            <p>5. Perkovic et al. (2019). "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy." NEJM.</p>
            <p>6. American Diabetes Association (2023). "Standards of Care in Diabetes‚Äî2023: Chronic Kidney Disease and Risk Management." Diabetes Care.</p>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Diabetes & Blood Sugar Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved.</p>
        </footer>
    </div>
</body>

</html>